Low Muscle Mass and Treatment Tolerance in Patients With Upper Gastrointestinal Cancer: A Systematic Review and Meta-Analysis

Abstract

A systematic review and meta-analysis of 49 studies looking at whether low skeletal muscle mass in people with upper gastrointestinal cancer having systemic treatment is linked to severe (grade 3–4) adverse events and to stopping treatment early. Low muscle mass was associated with a higher risk of grade 3–4 adverse events (RR 1.44, 95% CI 1.23–1.68) and of treatment discontinuation (RR 2.39, 95% CI 1.87–3.07). Most studies had a high risk of bias, so prospective confirmatory studies are needed.

Publication
JCSM Communications, 8(1)
Edward N Stanhope
Edward N Stanhope
Senior Lecturer in Sport Therapy & Assistant Professor, Programme Director, Clinical Trials (LSHTM)

Edward is a Senior Lecturer in Sport Therapy at the University of Staffordshire and Assistant Professor and Programme Director for the MSc Clinical Trials (Distance Learning) at the London School of Hygiene & Tropical Medicine. His research focuses on exercise and physical activity for people living with cancer and other non-communicable diseases, and on clinical trial methodology.

Related